An overview of our work

Our mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.

Our vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease.


MMV is a leading product development partnership (PDP) in antimalarial drug research and is in its 20th year. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and delivering new, effective and affordable antimalarial drugs.

Since its foundation in 1999, MMV and partners have developed and brought forward eleven new medicines: these include Krintafel/Kozenis* (tafenoquine), a single-dose anti-relapse treatment developed with GSK and for uncomplicated malaria, Pyramax® and Pyramax® Granules for children (pyronaridine-artesunate) with Shin Poong, Eurartesim® (dihydroartemisinin-piperaquine) with Sigma-Tau, as well as the first high-quality child-friendly formulation, Coartem® Dispersible (artemether-lumefantrine), with Novartis. The further six products have been brought forward by providing significant support to attain WHO prequalification. This includes two injectable artesunate products for the treatment of severe malaria, Artesun® from Guilin and Larinate 60 from Ipca Laboratories, two sulfadoxine–pyrimethamine + artesunate amodiaquine (SPAQ) for seasonal malaria chemoprevention from Guilin and S Kant Health, and two rectal artesunate (RAS) products for the pre-referral management of severe malaria from Cipla and Strides Pharma.

In addition, MMV has taken over the stewardship of two other medicines for uncomplicated malaria developed by Drugs for Neglected Diseases initiative (DNDi) and partners – ASAQ Winthrop® (artesunate-amodiaquine) and ASMQ (artesunate-mefloquine).

The impact of these new antimalarials has been impressive. Since 2009, over 385 million courses of Coartem Dispersible treatment have been supplied to over 50 malaria-endemic countries; and since prequalification in 2010, an estimated 128 million vials of Artesun have been delivered, saving 840,000 additional lives, compared to treatment with quinine. In total, an estimated 1.9 million lives have been saved by MMV-supported drugs.

MMV and partners manage a portfolio of over 65 projects, the largest portfolio of antimalarial R&D and access projects ever assembled. The portfolio includes ten compounds in clinical development addressing unmet medical needs in malaria, including medicines for children, pregnant women and relapsing malaria, and drugs that could support the elimination/eradication agenda. MMV’s success in research and access & product management comes from its more than 150 active global partnerships. Since its inception in 1999, MMV has built an extensive network of over 400 pharmaceutical, academic and endemic-country partners in more than 55 countries.

MMV’s vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease.

MMV’s work is only possible due to the support of our partners and committed donors.

*Trademarks owned or licensed by GSK